TY - JOUR T1 - COVID-19 vaccine hesitancy January-March 2021 among 18-64 year old US adults by employment and occupation JF - medRxiv DO - 10.1101/2021.04.20.21255821 SP - 2021.04.20.21255821 AU - Wendy C King AU - Max Rubinstein AU - Alex Reinhart AU - Robin J. Mejia Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/24/2021.04.20.21255821.abstract N2 - Introduction COVID-19 vaccine hesitancy increased among US adults April-December, 2020, and threatens efforts to end the pandemic. Among US adults 18-64 years, we report prevalence of and reasons for vaccine hesitancy, overall and by employment and occupation, during the COVID-19 vaccine rollout.Methods The Delphi Group at Carnegie Mellon University conducted a COVID-19 survey administered by Facebook. In January, February and March, 2021, 791,716, 710,529, and 732,308 Facebook users, respectively, reported age 18-64 years and answered a vaccine acceptance question. Weights matched the sample to the age, gender, and state profile of the US population. Percentages and risk ratios (RR) for vaccine hesitancy were estimated using a weighted Poisson regression; 95% confidence intervals (CI) were calculated using robust standard errors.Results Vaccine hesitancy decreased among adults 18-64 years from January (27.5% [95%CI, 27.3-27.6]) to March (22.1% [95%CI, 21.9-22.2]). Vaccine hesitancy varied widely by occupational category: 9.6%, (95%CI, 8.5-10.7) in life/physical/social sciences to 46.4% (95%CI, 45.1-47.7) in construction/extraction. Almost half (47.9%, 95%, 47.6-48.3) of hesitant participants indicated concern about side effects, and over a third didn’t believe they needed the vaccine, didn’t trust the government, were waiting to see if it was safe, and didn’t trust COVID-19 vaccines (versus 14.5% [95%CI, 14.3-14.8] who didn’t like vaccines in general).Conclusions In this nationally representative survey of adults 18-64 years, vaccine hesitancy decreased to 22.1% by March, 2021. Still, hesitancy, which varies widely by occupation, remains a barrier to pandemic control. Reasons for hesitancy indicate messaging about safety and addressing trust are paramount.Competing Interest StatementDr. King, Dr. Mejia and Mr. Rubenstein have no conflict of interest to report. Dr. Reinhart received salary support from an unrestricted monetary gift Facebook.Clinical Protocols https://delphi.cmu.edu/covidcast/surveys/ Funding StatementDr. King, Dr. Mejia and Mr. Rubenstein have no conflict of interest to report. Dr. Reinhart received salary support from an unrestricted gift from Facebook. Funding/Support: This material is based upon work supported by Facebook (unrestricted gift) and a research grant from the Centers for Disease Control and Prevention (U01IP001121). Any opinions, findings and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of Facebook or the Centers for Disease Control and Prevention. Role of the Funder: Facebook was involved in the design and conduct of the study. The CDC provided funding only. Neither Facebook nor the Centers for Disease Control and Prevention had a role in the collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Carnegie Mellon University (CMU) CMU Institutional Review Board approved the survey protocol and instrument: STUDY2020_00000162All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIf you are interested in using the survey data for your research, you can start the process by submitting a form requesting a data use agreement (DUA) from Facebook. The data is not available from the authors. https://dataforgood.fb.com/docs/covid-19-symptom-survey-request-for-data-access/ ER -